Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afraxis Inc.

This article was originally published in Start Up

Executive Summary

Afraxis Inc. is developing p21-activated kinase (PAK) inhibitors, initially for Fragile X syndrome, a genetic condition involving changes in the X chromosome that can lead to cognitive impairment and autism-like behaviors. The start-up thinks treatment of this orphan indication may be a gateway to developing PAK inhibitors for closely related conditions, such as autism and other central nervous system disorders like Alzheimer's disease and schizophrenia.
Advertisement

Related Content

Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases
Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases
Edimer Pharmaceuticals Inc.
Start-Up Previews (05/2011)
bluebird bio LLC
Rare Disease Research: Where Compassion Meets Commerce
Ultragenyx Pharmaceutical LLC
Start-Up Previews (05/2011)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel